VCD (bortezomib, cyclophosphamide and dexamethasone) is an effective chemotherapy combination commonly used for the treatment of newly diagnosed multiple myeloma (MM), while bortezomib combined with isatuximab has shown potential in MM xenograft models. Thus, the combination of isatuximab with VCD (VCDI) is a promising one. Here, Enrique Ocio, MD, PhD, from University Hospital of Salamanca, Salamanca, Spain, provides an update on the Phase Ib study (NCT02513186) of VCDI in newly diagnosed MM patients who are ineligible for transplantation. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, he discusses the promising results of the initial data and the next stage of this research.
